The small MAF transcription factors MAFF, MAFG and MAFK: Current knowledge and perspectives  by Kannan, Meenakshi B. et al.
Biochimica et Biophysica Acta 1823 (2012) 1841–1846
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrReview
The small MAF transcription factors MAFF, MAFG and MAFK: Current knowledge
and perspectives
Meenakshi B. Kannan a,b, Vera Solovieva a,b, Volker Blank a,b,c,⁎
a Lady Davis Institute for Medical Research, McGill University, Montreal, QC, Canada
b Department of Medicine, McGill University, Montreal, QC, Canada
c Department of Physiology, McGill University, Montreal, QC, Canada⁎ Corresponding author at: Lady Davis Institute for Me
Medicine, McGill University, 3755 Cote Sainte-Catherine
H3T 1E2. Tel.: +1 514 340 8260x4984.
E-mail address: volker.blank@mcgill.ca (V. Blank).
0167-4889/$ – see front matter © 2012 Elsevier B.V. All
doi:10.1016/j.bbamcr.2012.06.012a b s t r a c ta r t i c l e i n f oArticle history:
Received 27 February 2012
Received in revised form 11 June 2012
Accepted 12 June 2012
Available online 18 June 2012
Keywords:
MAF
bZIP
CNC
Gene regulation
Stress signaling
CancerThe small MAFs, MAFF, MAFG and MAFK have emerged as crucial regulators of mammalian gene expression.
Previous studies have linked small MAF function, by virtue of their heterodimerization with the Cap ‘n’ Collar
(CNC) family of transcription factors, to the stress response and detoxiﬁcation pathways. Recent analyses
have revealed a complex regulatory network involving small MAF transcription factors and other cellular
proteins. The expression and activity of small MAFs are tightly regulated at multiple levels. With regard to
their clinical importance, small MAFs have been linked to various diseases, such as diabetes, neuronal disorders,
thrombocytopenia and carcinogenesis. A better understanding of the molecular mechanisms governing the
activity of small MAFs will provide novel insights into the control of mammalian transcription and may lead to
the development of novel therapeutic strategies to treat common human disorders.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The advent of theMAF (proto-) oncogene family beganwith the dis-
covery of the foundingmember, the oncogene v-Maf, whichwas identi-
ﬁed during the analysis of the avian transforming retrovirus isolated
from chicken musculoaponeurotic ﬁbrosarcoma (Maf) [1]. The MAFs
are members of the basic leucine zipper (bZIP) family of transcription
factors, which also includes AP-1, CREB/ATF, CNC, C/EBP and PAR
proteins [2].
The MAF proteins, like other members of the bZIP family, possess
evolutionary conserved basic and leucine zipper domains. The basic
domain binds DNA, whereas the leucine zipper mediates homo- or
hetero-dimerizationwith speciﬁc bZIP transcription factors. MAF family
members can be divided into two groups, small and largeMAF proteins.
The large MAFs, including C-MAF, MAFA/L-MAF, MAFB/KREISLER and
NRL proteins, contain an acidic N-terminal transactivation domain and
play key roles in mammalian gene regulation, cellular differentiation
and oncogenesis [3–5]. The small MAFs, MAFF, MAFK and MAFG are
highly homologous proteins of about 18 kDa in molecular weight
[6,7], and are localized predominantly in the nucleus [8–10]. The small
MAFs display a complex expression pattern during embryogenesis
[11–14]. In adult mice, the small MAFs are expressed in a wide varietydical Research, Department of
Rd, Montreal, Quebec, Canada
rights reserved.of tissues, albeit at various levels [15–18]. Despite the lack of an evident
transactivation domain, the small MAFs have emerged as important
transcriptional regulators [19].
A series of comprehensive articles onMAF proteins has covered var-
ious aspects of the biology of these intriguing transcriptional regulators
[3–5,19–22]. The present review serves as an update, describing new
insights into the regulation and function of small MAF transcription
factors as well as their roles in disease pathology.
2. Multifaceted small MAF regulatory networks
Small MAF proteins form heterodimers withmembers of the Cap ‘n’
Collar (CNC) transcription factor family that includes NFE2 [nuclear fac-
tor (erythroid-derived 2), 45 kDa], NFE2L1 [nuclear factor (erythroid-
derived 2)-like 1, also known as NRF1], NFE2L2 (NRF2), NFE2L3
(NRF3) and the more distantly related BACH1 and BACH2. In addition,
the small MAFs have been shown to interact with several different pro-
teins (Table 1) resulting in a complex interactome [19,20]. The small
MAFs can also homodimerize and act, especially upon overexpression,
as transcriptional repressors [21,23]. Small MAFs, heterodimerizing
with other bZIP transcription factors, can act either as transcriptional
activators or repressors depending on their dimerization partners
[19]. The members of the CNC family of transcription factors, which
lack the capacity to bindDNAon their own, require smallMAFs as oblig-
atory dimerization partners for their function as transcriptional regu-
lators. The MAF recognition element (MARE) sequence typically
comprises TPA-responsive element (TRE) or cyclic AMP-responsive
Table 1
Interactome of small MAF proteins.
Protein Interaction with small MAF References
Leucine zipper proteins
MAFF + [69]
MAFG + [69]
MAFK + [69]
NFE2 P45 + [15,69,70]
NFE2L1 + [15,70–72]
NFE2L2 + [15,69,70,72–74]
NFE2L3 + [75,76]
BACH1 + [77]
BACH2 + [77]
FOS + [69]
FOSB + [78]
MIP + [79]
v-MAF − [80]
MAFB − [80]
JUN − [70]
Other proteins
HOX12 + [81]
MHOX/PRX1/PHOX1/PMX1 + [81]
PAX6 + [81]
HIF1A + [29]
MATIIA + [32]
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AP-1 and CREB/ATF families of transcription factors. This overlap in
the binding motifs leads to complexity in the elucidation of small MAF
function. In addition, a GC ﬂanking element outside this core sequence
has been found to be important for the binding of small MAFs. Two
residues in the basic region, directly interacting with the extended GC
bases, have recently been shown to play a crucial role in MAF-speciﬁc
DNA recognition [25]. The transcriptional activity is highly dependentFig. 1. Cellular functions of small MAFs. Small MAFs, which are induced in response to cellula
other proteins. They bind to speciﬁc recognition sites and control the genes involved in var
sumoylation, which have been shown to regulate their transcriptional activity.on the respective levels of the CNC and small MAF proteins within the
cell [21,26]. Using in vivo models, it has also been shown that positive
or negative MARE-dependent transcriptional regulation is dependent
on the abundance of small MAF proteins [27]. Based on studies from
various laboratories [3,4,19–22], a model of the cellular network of
small MAF transcription factors is shown (Fig. 1).
Recent studies shed light on additional components of the cellular
functions of small MAF proteins. MAFG has been shown to regulate
the intracellular localization of NFE2L2, thereby controlling its tran-
scriptional activity. Heterodimerization with MAFG increased the
nuclear retention of NFE2L2, by masking the nuclear export signal
(NES) located in the bZIP domain of NFE2L2, thus rendering it inacces-
sible to thenuclear exporting protein, chromosome regionmaintenance
1 (CRM1) [28]. Since NFE2L2 is a protein with a rapid turnover, it was
proposed that heterodimerization with MAFG leads to its stabilization
by promoting cytosolic exclusion and nuclear accumulation.
Newer data also link small MAFs to the hypoxic response. MAFG has
been found to interact with hypoxia inducible factor 1, alpha subunit
(HIF1A), a key transcription factor involved in the hypoxic response and
a member of the basic helix–loop–helix–per/ARNT/Sim (bHLH-PAS)
family. Physical interaction between MAFG and one of the two PAS
domains, PAS-A, of HIF1A has been shown by using a yeast two-
hybrid assay and conﬁrmed by surface plasmon resonance. MAFG
knockdown attenuated nuclear accumulation of HIF1A and repressed
its hypoxic response. Knockdown of MAFG also led to a signiﬁcant
decrease in the transcript levels of erythropoietin, a knownHIF1A target
gene, upon induction of hypoxia in Hep3B cells [29]. Of note, gene
expression proﬁling using ATDC5 chondrocyte cells revealed also an
upregulation of MAFF transcripts under hypoxic conditions [30].
New data have also revealed a connection between small MAFs
and methionine adenosyltransferase II A (MATIIA), an enzyme that is
required for the catalysis of the methyl donor S-adenosylmethionine.r stress, are able to homodimerize or heterodimerize with CNC transcription factors and
ious cellular processes. Small MAFs are post-translationally modiﬁed by acetylation or
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ulated by MAFK [31], and a recent proteomics study found that MATIIA
is recruited to the HMOX1 gene locus in X63/0 and Hepa1 cells and
revealed a physical interaction between MAFK and MATIIA. The knock-
down of MATIIA resulted in derepression of HMOX1. Since MAFK has
been previously shown to modulate HMOX1 gene expression, it is
proposed that MATIIA could act as a corepressor of MAFK, together reg-
ulating the mRNA and protein levels of HMOX1 [32]. MAFG has also
been linked to MATIIA, as this small MAF protein can induce MATIIA
via insulin growth factor-1 (IGF1). Knockdown of MAFG lowered basal
MATIIA levels and reduced IGF-1 mediated induction of MATIIA [33].
Novel studies also implicated MAFK in impaired erythroid matura-
tion mediated by the 89 kDa zinc ﬁnger protein (ZBP-89). ZBP-89 has
been reported to have a direct role in the regulation of human globin
and other erythroid-speciﬁc gene expression. Lower ZBP-89 levels are
associated with lower globin and erythroid-speciﬁc gene expression,
and were linked to impaired erythroid maturation [34]. Interestingly,
an earlier quantitative proteomic analysis had shown physical inter-
action between ZBP-89 and the MAFK/NFE2 heterodimer during the
induction of mouse erythroleukemia (MEL) cell differentiation [9].
In the animal biology ﬁeld, a recent study showed a link between
MAFG and the regulation of HMOX1 in hibernating mammals. Hiber-
nation comprises long periods of deep torpor interspersed by short
periods of arousal, during which an efﬁcient antioxidant defense mech-
anism is required to defend against the high levels of reactive oxygen
species (ROS) generated. HMOX1 is increased at both transcript and
protein levels in the tissues of hibernating ground squirrels. Of interest,
increased levels of NFE2L2 and MAFG were reported in various organs
of hibernating mammals [35]. Further analyses in hibernating ground
squirrels revealed an increase ofMAFG protein in brown adipose tissue,
liver, heart and lungs, along with increased nuclear accumulation of
MAFG in liver cells [36]. These data suggest a role for this small MAF
protein in the induction of HMOX1 during mammalian hibernation.3. Posttranslational modiﬁcations controlling small MAF activity
A series of studies revealed that small MAFs are regulated by post-
translational modiﬁcations. The cAMP-response element-binding
protein (CREB)-binding protein (CBP) has previously been shown to
acetylate MAFG in erythroid cells. Acetylation of MAFG was shown to
enhance the transcriptional activity of the NFE2/MAFG heterodimer
and augment its DNA binding activity, suggesting that acetylation of
MAFG plays a vital role in transcriptional control [37]. The p65 subunit
of NFKB transcription factor has been shown to regulate gene expres-
sion through the recruitment of speciﬁc coactivators such as CBP or
corepressors like histone deacetylases. NFKB p65 has recently been
shown to repress the NFE2L2–ARE pathway, which has an established
role in inﬂammation and cancer, by two different mechanisms. Firstly,
NFKB p65 speciﬁcally inhibits the binding of CBP, the principal
coactivator of NFE2L2, thereby inhibiting the NFE2L2–ARE pathway.
Secondly, NFKB p65 was found to promote MAFK-associated HDAC
recruitment to the ARE locus of the HMOX1 enhancer. This enhanced
HDAC recruitment promotes deacetylation of MAFK and CBP, which
antagonizes MAFK co-transcriptional activity and also abolishes CBP
coactivator function [38]. This study reveals a novel link between
MAFK acetylation status and NFKB p65-mediated NFE2L2–ARE tran-
scriptional control.
Sumoylation is another protein modiﬁcation that has previously
been found to be involved in the control of small MAF activity. It has
been shown that MAFG is conjugated to SUMO-2/3 both in vivo and
in mouse bone marrow cells. Sumoylation is required for the repressor
activity of MAFG and this modiﬁcation counteracts transcriptional acti-
vation mediated by the NFE2–MAFG heterodimer [39]. Whether the
other small MAF proteins are controlled by sumoylation is yet to be
brought to light.4. Role of small MAF proteins in detoxiﬁcation
Cellular studies have revealed links between smallMAF proteins and
stress response/detoxiﬁcation pathways. Small MAF homodimers and
CNC/small MAF heterodimers recognize MARE sequences, which re-
semble the antioxidant response element (ARE) found in the regulatory
regions of many phase II drug-metabolizing enzyme and antioxidant
genes [19,20,40,41]. Single and compound small MAF knockout mouse
models have been generated and their phenotype has been discussed
previously [19,20]. Mice lacking all three small MAF proteins have
been shown to be embryonic lethal and genechip expression array anal-
ysis of mouse embryonic ﬁbroblasts (MEF) generated from these mice
showed that small MAF proteins are essential for the activation of
genes involved in stress response and detoxiﬁcation [41]. A recent
follow-up study reported that the triple knockout embryos that lack
the three small MAFs develop normally until embryonic day E9.5, but
subsequently display growth retardation and liver hypoplasia and die
approximately at E13.5. The transcript levels of cytoprotective genes
were normal in E10.5 triple knockout embryos, but a signiﬁcant reduc-
tion in the expression of these genes was observed in the fetal liver at
E13.5 combined with enhanced apoptosis of hepatocytes and erythroid
cells [42]. This study demonstrates the signiﬁcance of small MAFs post
E9.5 during embryogenesis and further supports the previous cellular
studies showing that small MAFs mediate stress response and detoxiﬁ-
cation via AREs.
5. Emerging roles of small MAFs in pathogenesis of
human diseases
Although small MAFs have been associated with the cellular stress
response, little is known about their speciﬁc roles in human health
and pathology. However, a few studies suggest relevant links be-
tween small MAFs and various disease pathologies including diabetes,
neurological diseases, thrombocytopenia and cancer (Table 2).
6. Potential role for small MAFs in diabetes
A role for small MAFs in the pathology of diabetes has recently
been revealed based on studies using cellular and transgenic mouse
models. MAFA, a member of the large MAF family, has previously
been shown to be involved in insulin gene transcription and pancre-
atic beta cell function [43–46]. Mice that lack Mafa (Mafa−/−) devel-
op diabetes mellitus (DM) due to impaired insulin gene transcription
and defective pancreatic islets [47]. Transgenic mice that overexpress
MAFK speciﬁcally in their beta cells (Mafk+) develop hyperglycemia
at a young age, but they do not develop DM, possibly due to an increase
of MAFA DNA binding activity in these mice that may compensate for
the overexpression of MAFK. To evade this possible functional redun-
dancy, transgenic Mafa−/− mice overexpressing MAFK speciﬁcally in
their beta cells (Mafa−/−Mafk+) were generated [48]. Mafa−/−Mafk+
mice, both male and female, developed DM at 5 weeks of age and
displayed a more severe phenotype when compared to the Mafa−/−
mice. The Mafa−/−Mafk+ mice manifested persistent hyperglycemia
and other histological features that are typical characteristics of
human diabetic nephropathy [48]. In this context, MAFK is believed to
act as a dominant negative protein antagonizing large MAF protein
function in pancreatic beta cells. Hence,MAFKoverexpression enhances
the diabetic phenotype of Mafa−/− animals and Mafa−/−Mafk+ mice
may thus serve as a valuable mouse model to investigate diabetic
pathogenesis.
Reduced levels and dysfunction of endothelial progenitor cells
(EPC) are known features of type-1 diabetes mellitus (DM1) [49].
Proﬁling of EPC gene expression in DM1 patients revealed the down-
regulation of MAFF, linking this transcription factor to DM1 pathology.
Interestingly, folic acid supplementation, which serves to the beneﬁt
of DM1 patients by restoring endothelial cell function, also restored
Table 2
Association of small MAFs with disease pathologies.
Disease phenotype Small Maf Observation Reference
Diabetes mellitus type 1 MAFF ∙ Downregulated in DM1 patients [50]
MAFK ∙ Overexpression in beta cells causes hyperglycemia
∙ Mafa−/− overexpressing MAFK in beta cells develop severe DM
[48]
Neuronal disease MAFG & MAFK ∙ Mafg−/−Mafk+/− mice develop progressive motor disorder [53]
MAFF ∙ Induced in Parkinson's disease patients by L-Sulforaphane [56]
Thrombocytopenia MAFG ∙ Mafg−/− mice develop thrombocytopenia
∙ MAFG expression is suppressed by human interferon (IFN)-alpha leading to thrombocytopenia
[57]
[61]
MAFG & MAFK ∙ Mafg−/− Mafk+/− mice develop severe thrombocytopenia [57]
Cancer MAFG ∙ MAFG expression levels are lower in smokers with lung cancer than in smokers without cancer or non-smokers
∙ Mir-218-mediated MAFG levels modulate the airway epithelial gene expression response to cigarette smoke,
with a potential relevance to lung cancer phenotype
∙ MAFG expression is induced by insulin-like growth factor-1 (IGF-1) in human colon cancers
[64]
[65]
[33]
MAFK ∙ Altered expression in speciﬁc acute myeloid leukemia cytogenetic group [67]
MAFF ∙ Lower in acute lymphoblastic lymphoma (ALL) patients with translocation t(12;21)
∙ MAFF is downregulated in diverse tumor types
[68]
[55]
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derlying this normalization has yet to be investigated.
7. Linking small MAFs to neuronal diseases
SmallMAFs have also been associatedwith speciﬁc neuronal pheno-
types. MAFKwas shown to be upregulated in PC12 pheochromocytoma
cells and in immature telencephalic neurons upon nerve growth factor
(NGF) treatment. It was found thatMAFK regulates nerve growth factor
(NGF)-promoted neurite generation and neuronal differentiation in
PC12 cells and immature telencephalon neurons, implying that it
plays a crucial role in neurite outgrowth and its maintenance [51].
MAFK was also found to be crucial for neurite outgrowth [52]. Com-
pound Mafg−/−Mafk−/−mice develop age- and Maff gene dosage-
dependent neurological defects such as progressive motor disorder,
neuronal degeneration, glycine receptor deﬁciency and also exhibit
alterations in MARE-dependent gene expression. These data highlight
the signiﬁcance of small MAFs in the maintenance of normal CNS func-
tion [53]. Concentration of small MAFs might play an important role in
neurological disorders and these proteins might emerge as novel tar-
gets for neuronal diseases. Supporting this notion further, the kinase
AKT, which negatively regulates neuronal differentiation and acts as a
neuronal protector against apoptosis, has been shown to suppress
MAFK expression in PC12 cells. BesidesMAFK, MAFF was also identiﬁed
as an NGF-responsive immediate-early gene (IEG) in amicroarray anal-
ysis conducted in PC12 cells [54], suggesting a role forMAFF in neuronal
cell division and development. It is noteworthy that mechanistically,
MAFF has been shown to abate epidermal growth factor (EGF)-induced
MAPK signaling [55], which plays a crucial role in neuronal differentia-
tion. Recently, it has been shown thatMAFF is differentially regulated in
Parkinson's disease patient-derived olfactory neurosphere-derived cells
[56]. Transcriptome analysis revealed an induction of MAFF in Par-
kinson's disease patients by L-sulforaphane, an inducer of NAD(P)H:
quinonereductase (QR1) and a potential candidate for development of
treatment of Parkinson's disease. L-Sulforaphane liberates NFE2L2
from its cytoplasmic inhibitor, KEAP1, in patients with Parkinson's
disease, whereas in healthy patients there was no such upregulation.
MAFG however, was induced in Parkinson's disease patients and
healthy individuals by L-sulforaphane. Together, the above studies
strongly suggest a role for small MAFs in neuronal differentiation and
function.
8. Small MAFs and thrombocytopenia
There have been recent advances in the understanding of the role
of small MAFs in thrombocytopenia. It is known that the Mafk−/−
mice exhibit reduced platelet production and that Mafg−/− miceheterozygous forMafk develop a more severe phenotype of thrombo-
cytopenia than single knockout Nfe2−/− mice [57]. MAFG expression
was found to be downregulated in transgenic mice lacking the
carboxy-terminal regulatory domain of Fli1 (Friend leukemia integra-
tion 1) gene. These homozygous Fli1 mutant mice exhibit reduced
viability, reduction in platelet levels, impaired platelet aggregation
and prolonged bleeding, suggesting a role for MAFG in megakaryocyte
biogenesis [58]. Analyzing transgenic mice expressing a mutant MAFG
protein, lacking the C terminus that were crossed into a Mafg−/− back-
ground, it was demonstrated that the C-terminus of MAFG plays a vital
role in platelet gene expression and activation. Intriguingly, the platelet
count was radically reduced in these compound mutant mice,
phenocopying Nfe2−/− mice [59]. This data is of interest, as the C-
termini of smallMAFs are one of the few regions that exhibit a lesser de-
gree of homology [19]. Mafg−/− mice, in addition to having impaired
platelet release, were also shown to compensate for the thrombocyto-
penia by increased levels of their proliferative progenitors. Bone mar-
row transplant studies using wild-type and Mafg−/− mice showed
that absence of MAFG leads to accelerated hematopoietic recovery
[60]. Along the same lines, MAFG transcript levels are suppressed in a
dose-dependent manner, by human interferon (IFN)-α treatment,
which is known to induce thrombocytopenia in chronic hepatitis C
patients [61].9. Contribution of small MAFs to cancer pathology
By virtue through their interaction with CNC transcription factors,
small MAF proteins have been clearly linked to carcinogenesis [62,63].
A few recent studies further exemplify the close association between
small MAFs and human cancer pathology. MAFG gene expression has
been found to be signiﬁcantly lower in smokers who developed lung
cancer when compared to smokers who did not. Interestingly, the
study identiﬁed several novel single-nucleotide polymorphisms
(SNPs) including one in the MAFG locus that correlated with MAFG
gene expression and another that was associated with lung cancer sta-
tus among smokers [64]. These data revealed a potential role for MAFG
in regulating smoking-induced gene expression and it could be specu-
lated that theMAFG gene locus is involved in lung cancer pathogenesis.
Consistently, in a whole genome-proﬁling study analyzing microRNA
mir-218 and mRNA levels of bronchial epithelial cells from smokers
and non-smokers, MAFG was shown to be one of the candidate genes
being upregulated in smokers. The study also showed decreased levels
of mir-218 expression and this inverse correlation between mir-218
and MAFG was validated by mir-218 knockdown and overexpression
experiments conducted in bronchial epithelial cell lines. Furthermore,
it has been shown in primary bronchial epithelial cells exposed to
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uated by overexpression of mir-218 [65].
Increased levels of IGF1 (insulin-like growth factor-1) have been as-
sociated with colon cancer growth and metastasis [66]. A recent study
found that IGF1 induced MAFG transcript levels in colon cancer cells
[33], revealing a potential role for this gene in colon cancer pathogene-
sis. Other studies linking small MAFs to cancer pathology include a pro-
teomics analysis that revealed distinctly altered expression ofMAFK in a
speciﬁc acute myeloid leukemia (AML) cytogenetic group [67] and a
microarray analysis in which MAFF expression was found to be lower
in acute lymphoblastic lymphoma (ALL) patients with translocation
t(12;21) when compared to healthy controls [68]. In summary, the
above studies impose a role for small MAFs in human cancer pathology
and suggest that small MAFsmay be valuable targets in cancer therapy.
10. Small MAF biology: unresolved questions and future outlook
Small MAFs play a signiﬁcant role in the oxidative stress response
and are involved in the transcriptional control of human diseases like
diabetes, neuronal disorders, thrombocytopenia and cancer, function-
ing in concert with other signaling proteins and transcription factors
forming a complex regulatory network. There have been remarkable
advances in our understanding of the biological functions of small
MAFs in the recent past, in particular with regard to their regulation
and potential roles in human diseases. However, there are a series of
studies that will lead to better knowledge of these transcription factors.
Although, small MAFs have been shown to be present predominantly in
the nucleus, further analyses on their sub-cellular localization and its
signiﬁcance are required to gain further information on the regulation
of these transcription factors at the cellular level. Despite recent pro-
gress, the importance of post-translational modiﬁcations in the control
of small MAF activity needs to be further investigated. To study the role
of smallMAFs in vivo, conditional animalmodels need to be established,
as triple MafF−/−MafG−/−MafK−/− knockout mice are embryonic
lethal [41]. These mouse models will serve as powerful tools for devel-
oping a more detailed understanding of the distinct roles of each of the
small MAFs in biological pathways, and might also provide novel
insights into their regulation and their signiﬁcance in disease pathology
in vivo. The complex interactions between small MAFs and various CNC
familymembers remain to be investigated in further detail. The study of
the role of small MAF transcription factors will be rewarding, as we
should obtain a better understanding of themammalian transcriptional
network and associated disease processes.
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